Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 149-160

  Farhat, Fadi S ^a   Tfayli, Arafat ^b   Fakhruddin, Najla ^a,b   Mahfouz, Rami ^b   Otrock, Zaher K ^b   Alameddine, Raafat S ^b   Awada, Ahmad H ^c   Shamseddine, Ali ^b  

^a Hammoud Hospital   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Angiogenic markers; BFGF; Expression; Non small cell lung cancer; Prognostic impact; Review; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; RAMUCIRUMAB; SORAFENIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HEMOPTYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867850068     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.012     Document Type: Review

References (120)

1. Sant M., Aareleid T., Berrino F., Bielska Lasota M., Carli P.M., Faivre J., et al. EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003, 14(Suppl. 5):v61-v118.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. World Health Organization World Health Statistics 2006 2006, World Health Organization, Geneva, Switzerland, Available at: http://www.who.int/whosis/whostat2006/en/index.html.
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Wheatley-Price P., Shepherd F.A. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008, 3:1173-1184.
6. Burris H.A. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009, 28(Suppl. 1):S4-S13.
7. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
8. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
9. Otrock Z.K., Makarem J.A., Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007, 38:258-268.
10. Pandya N.M., Dhalla N.S., Santani D.D. Angiogenesis-a new target for future therapy. Vascul Pharmacol 2006, 44:265-274.
11. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6.
12. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
13. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
14. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
15. Keith R.L., Miller Y.E., Gemmill R.M., Drabkin H.A., Dempsey E.C., Kennedy T.C., et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000, 6:1616-1625.
16. Fontanini G., Calcinai A., Boldrini L., Lucchi M., Mussi A., Angeletti C.A., et al. Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 1999, 6:813-817.
17. Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19:1207-1225.
18. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007, 39:212-220.
19. Mountzios G., Dimopoulos M.A., Soria J.C., Sanoudou D., Papadimitriou C.A. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol 2010, 75:94-109.
20. Custodio A., de Castro J. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. Crit Rev Oncol Hematol 2011, (September). [Epub ahead of print].
21. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
22. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
23. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
24. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407-1412.
25. Quinton C., Ellis P.M. An evidence-based approach to the use of predictive biomarkers in the treatment of non- small cell lung cancer (NSCLC). Cancers 2011, 3:3506-3524.
26. Leighl N., Reck M., de Haas S., Evers S., Delmar P., Manegold C., et al. Analysis of biomarkers (bms) in the avail phase iii randomised study of first-line bevacizumab (bv) with cisplatin-gemcitabine (cg) in patients (pts) with non-small cell lung cancer (NSCLC). Eur J Cancer 2009, (Suppl. 7):558.
27. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:5407-5415.
28. Heymach J.V., Johnson B.E., Prager D., Csada E., Roubec J., Pesek M., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
29. Natale R.B., Bodkin D., Govindan R., Sleckman B.G., Rizvi N.A., Capó A., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009, 27:2523-2529.
30. Hanrahan E.O., Ryan A.J., Mann H., Kennedy S.J., Langmuir P., Natale R.B., et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15:3600-3609.
31. Hanrahan E.O., Lin H.Y., Kim E.S., Yan S., Du D.Z., McKee K.S., et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010, 28:193-201.
32. Longo R., Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007, 60:151-170.
33. Nikolinakos P.G., Altorki N., Yankelevitz D., Tran H.T., Yan S., Rajagopalan D., et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010, 70:2171-2179.
34. Gold K.A., Kim E.S., Lee J.J., Wistuba I.I., Farhangfar C.J., Hong W.K. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 2011, 4:962-972.
35. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
36. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028-1043.
37. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
38. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
39. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
40. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5:1806-1814.
41. Suto K., Yamazaki Y., Morita T., Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005, 280:2126-2131.
42. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
43. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003, 28:488-494.
44. Nash A.D., Baca M., Wright C., Scotney P.D. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 2006, 19:61-69.
45. Mould A.W., Tonks I.D., Cahill M.M., Cahill M.M., Pettit A.R., Thomas R., et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum 2003, 48:2660-2669.
46. Bellomo D., Headrick J.P., Silins G.U., Paterson C.A., Thomas P.S., Gartside M., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000, 86:E29-E35.
47. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997, 16:3898-3911.
48. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004, 5:74-80.
49. Skobe M., Hamberg L.M., Hawighorst T., Schirner M., Wolf G.L., Alitalo K., et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001, 159:893-903.
50. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
51. Fujimoto J., Toyoki H., Sato E., Sakaguchi H., Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer 2004, 91:466-469.
52. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
53. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Guidi A.J., Dvorak H.F., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91.
54. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Senger D.R., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53:4727-4735.
55. Olson T.A., Mohanraj D., Carson L.F., Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994, 54:276-280.
56. Guidi A.J., Abu-Jawdeh G., Berse B., Jackman R.W., Tognazzi K., Dvorak H.F., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87:1237-1245.
57. Mattern J., Koomägi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73:931-934.
58. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996, 2:1411-1416.
59. Volm M., Koomägi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997, 74:64-68.
60. Mattern J., Koomägi R., Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res 1997, 17:2249-2252.
61. Ohta Y., Tanaka Y., Watanabe G., Minato H. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J Exp Clin Cancer Res 2007, 26:301-305.
62. Giatromanolaki A., Koukourakis M.I., Kakolyris S., Turley H., O'Byrne K., Scott P.A., et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998, 4:3017-3024.
63. Fontanini G., Vignati S., Boldrini L., Chinè S., Silvestri V., Lucchi M., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861-865.
64. Imoto H., Osaki T., Taga S., Ohgami A., Ichiyoshi Y., Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115:1007-1014.
65. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001, 19:432-441.
66. Yuan A., Yu C.J., Luh K.T., Kuo S.H., Lee Y.C., Yang P.C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 2002, 20:900-910.
67. Yuan A., Yu C.J., Shun C.T., Luh K.T., Kuo S.H., Lee Y.C., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005, 115:545-555.
68. Nakashima T., Huang C.L., Liu D., Kameyama K., Masuya D., Ueno M., et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 2004, 10:BR157-BR165.
69. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92:1231-1239.
70. Tanaka F., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002, 62:7124-7129.
71. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., Cox G., Turley H., Steward W.P., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000, 82:1427-1432.
72. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8:72-79.
73. Shibusa T., Shijubo N., Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 1998, 4:1483-1487.
74. Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., et al. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 1998, 12:541-544.
75. Takahama M., Tsutsumi M., Tsujiuchi T., Kido A., Okajima E., Nezu K., et al. Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers. Jpn J Clin Oncol 1998, 28:176-181.
76. Kadota K., Huang C.L., Liu D., Ueno M., Kushida Y., Haba R., et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 2008, 44:1057-1067.
77. Liao M., Wang H., Lin Z., Feng J., Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001, 33:125-132.
78. Baillie R., Carlile J., Pendleton N., Schor A.M. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 2001, 54:116-120.
79. Delmotte P., Martin B., Paesmans M., Berghmans T., Mascaux C., Meert A.P., et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir 2002, 19:577-584. [article in French].
80. Zhan P., Wang J., Lv X.J., Wang Q., Qiu L.X., Lin X.Q., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009, 4:1094-1103.
81. Carrillo de Santa Pau E., Arias F.C., Caso Peláez E., Muñoz Molina G.M., Sánchez Hernández I., Muguruza Trueba I., et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009, 115:1701-1712.
82. Donnem T., Andersen S., Al-Saad S., Al-Shibli K., Busund L.T., Bremnes R.M. Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer 2011, 12:106-115.
83. Bonnesen B., Pappot H., Holmstav J., Skov B.G. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2009, 66:314-318.
84. Pathak A.P., Hochfeld W.E., Goodman S.L., Pepper M.S. Circulating and imaging markers for angiogenesis. Angiogenesis 2008, 11:321-335.
85. Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994, 31(1221):211-214.
86. Bremnes R.M., Camps C., Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006, 51:143-158.
87. Brattström D., Bergqvist M., Hesselius P., Larsson A., Lamberg K., Wernlund J., et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002, 37:57-63.
88. Brattström D., Bergqvist M., Hesselius P., Larsson A., Wagenius G., Brodin O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004, 43:55-62.
89. Laack E., Köhler A., Kugler C., Dierlamm T., Knuffmann C., Vohwinkel G., et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002, 13:1550-1557.
90. Laack E., Scheffler A., Burkholder I., Boeters I., Andritzky B., Schuch G., et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005, 50:51-58.
91. Kaya A., Ciledag A., Gulbay B.E., Poyraz B.M., Celik G., Sen E., et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004, 98:632-636.
92. Chakra M., Pujol J.L., Lamy P.J., Bozonnat M.C., Quantin X., Jacot W., et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008, 3:1119-1126.
93. Jantus-Lewintre E., Sanmartín E., Sirera R., Blasco A., Sanchez J.J., Tarón M., et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer 2011, 74:326-331.
94. Choi J.H., Kim H.C., Lim H.Y., Nam D.K., Kim H.S., Yi J.W., et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001, 33:171-179.
95. Suzuki M., Iizasa T., Ko E., Baba M., Saitoh Y., Shibuya K., et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002, 35:29-34.
96. Park S.H., Lee S.S. The relationship between serum VEGF concentration and prognosis of lung cancer. Korean J Intern Med 2003, 18:207-211.
97. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006, 24:576-580.
98. Maniwa Y., Okada M., Ishii N., Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998, 114:1668-1675.
99. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J 2001, 48:43-47.
100. Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol 1992, 3:81-87.
101. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
102. Tsai J.C., Goldman C.K., Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995, 82:864-873.
103. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993, 69:508-517.
104. Asahara T., Bauters C., Zheng L.P., Takeshita S., Bunting S., Ferrara N., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
105. Florkiewicz R.Z., Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci USA 1989, 86:3978-3981.
106. Yu P.J., Ferrari G., Galloway A.C., Mignatti P., Pintucci G. Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. J Cell Biochem 2007, 100:1100-1108.
107. Fukushima Y., Byers M.G., Fiddes J.C., Shows T.B. The human basic fibroblast growth factor gene (FGFB) is assigned to chromosome 4q25. Cytogenet Cell Genet 1990, 54:159-160.
108. Gualandris A., Rusnati M., Belleri M., Nelli E.E., Bastaki M., Molinari-Tosatti M.P., et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996, 7:147-160.
109. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86:356-361.
110. Kuhn H., Köpff C., Konrad J., Riedel A., Gessner C., Wirtz H. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 2004, 44:167-174.
111. Takanami I., Imamura T., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., et al. Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn J Clin Oncol 1996, 26:293-297.
112. Volm M., Koomägi R., Mattern J., Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 1997, 33:691-693.
113. Shou Y., Hirano T., Gong Y., Kato Y., Yoshida K., Ohira T., et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001, 85:1706-1712.
114. Iwasaki A., Kuwahara M., Yoshinaga Y., Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004, 25:443-448.
115. Fujimoto K., Ichimori Y., Kakizoe T., Okajima E., Sakamoto H., Sugimura T., et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 1991, 180:386-392.
116. Brattström D., Bergqvist M., Larsson A., Holmertz J., Hesselius P., Rosenberg L., et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998, 18:1123-1127.
117. Ueno K., Inoue Y., Kawaguchi T., Hosoe S., Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001, 31:213-219.
118. Joensuu H., Anttonen A., Eriksson M., Mäkitaro R., Alfthan H., Kinnula V., et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002, 62:5210-5217.
119. Otrock Z.K., Hatoum H.A., Musallam K.M., Awada A.H., Shamseddine A.I. Is VEGF a predictive biomarker to anti-angiogenic therapy?. Crit Rev Oncol Hematol 2011, 79:103-111.
120. Blackburn E.H. Cancer interception. Cancer Prev Res (Phila) 2011, 4:787-792.